Methoxyflurane
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Methoxyflurane
Methoxyflurane: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Methoxyflurane, so there is currently no new predicted indication. The recorded uses for this drug are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 0 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 3489P | Penthrox (Combination Pack) | Liquid for inhalation 999 mg per g, 3 mL | Valid |
Safety Considerations
- Drug Interactions: 51 interactions were identified. Major interactions include:
- Doxycycline
- Tetracycline
- Minocycline
- Epinephrine
- Iothalamic acid
Moderate interactions include morphine, opium, ethanol, amphotericin B (several formulations), aminoglycosides (neomycin, streptomycin), vancomycin, exenatide, and aminosalicylates (mesalazine, balsalazide, olsalazine, sulfasalazine).
For warnings and contraindications, please refer to the TGA-approved Product Information (PI) for safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.